PT  - JOURNAL ARTICLE
AU  - Julia Bucklan
AU  - Zubair Ahmed
TI  - CGRP antagonists for decreasing migraine frequency: New options, long overdue
AID  - 10.3949/ccjm.87a.19048
DP  - 2020 Apr 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 211--218
VI  - 87
IP  - 4
4099  - http://www.ccjm.org/content/87/4/211.short
4100  - http://www.ccjm.org/content/87/4/211.full
SO  - Cleve Clin J Med2020 Apr 01; 87
AB  - The cornerstone of preventive migraine treatment has long been drugs developed for other diseases such as epilepsy, depression, and hypertension. But a new set of drugs is available for preventing migraine attacks: erenumab, galcanezumab, fremanezumab, and eptinezumab. These monoclonal antibodies target calcitonin gene-related peptide (CGRP) or its receptors, each a key molecule in the pathophysiology of migraine.